Supriya Lifescience Limited IPO (Supriya Lifescience IPO)

DetailSupriya Lifescience IPO bought in multiple times on conclusive day, retail segment booked 37.28 times

Supriya Lifescience is occupied with the assembling of Active drug fixings (APIs). As of March 31, 2021, the organization produces 38 APIs zeroed in on different helpful fragments, for example, allergy medicine, pain relieving, sedative, nutrient, hostile to asthmatic and against hypersensitive. The organization has been the biggest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The organization is likewise perhaps the biggest exporter of Salbutamol Sulfate from India in FY 2021 as far as volume.

In Fiscal 2021, the organization’s items were traded to 86 nations to 1,296 clients including 346 wholesalers. The organization has API business in Europe, Latin America, Asia, and North America.

Supriya Lifescience has an advanced assembling office in Maharashtra spread across 23,806 sq. mts, having a reactor limit of 547 KL/day including 7 clean rooms. The organization has likewise gained a plot of land, admeasuring 12,551 sq. mt, close to the current assembling office, to grow its assembling framework. The organization’s assembling office has gotten endorsements from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (recently known as SFDA)- China, Health Canada, comparable to API items being traded to the pertinent locales by the organization.

Organization Promoters:

Satish Waman Wagh is the organization advertiser.

Organization Financials:

For the year/time frame finished (₹ in Millions)

Particulars
	30-Sep-21	31-Mar-21	31-Mar-20	31-Mar-19
All out Assets	5,041.02	4,458.24	3,364.01	2,530.52
All out Revenue	2,300.61	3,962.21	3,227.13	2,858.62
Benefit After Tax	659.59	1,238.28	733.74	394.24

Objects of the Issue:

•             Subsidizing capital consumption necessities of the organization

•             Reimbursement as well as pre-installment, in full or part, of specific borrowings benefited by the organization and

•             General corporate purposes

Supriya Lifescience IPO Details

Initial public offering Opening Date          Dec 16, 2021

Initial public offering Closing Date             Dec 20, 2021

Issue Type           Book Built Issue IPO

Face Value          ₹2 per value share

Initial public offering Price            ₹265 to ₹274 per value share

Market Lot          54 Shares

Min Order Quantity         54 Shares

Posting At            BSE, NSE

Issue Size             [.] Eq Shares of ₹2

(amassing up to ₹700.00 Cr)

New Issue           [.] Eq Shares of ₹2

(amassing up to ₹200.00 Cr)

Offer for Sale     [.] Eq Shares of ₹2

(amassing up to ₹500.00 Cr)

QIB Shares Offered         Not under 75% of the Offer

Retail Shares Offered     Not over 10% of the Offer

NII (HNI) Shares Offered Not over 15% of the Offer

Supriya Lifescience IPO Tentative Timetable

The Supriya Lifescience IPO open date is Dec 16, 2021, and the nearby date is Dec 20, 2021. The issue might list on Dec 28, 2021.

Initial public offering Open Date Dec 16, 2021

Initial public offering Close Date Dec 20, 2021

Premise of Allotment Date           Dec 23, 2021

Commencement of Refunds       Dec 24, 2021

Credit of Shares to Demat Account           Dec 27, 2021

Initial public offering Listing Date              Dec 28, 2021

Supriya Lifescience IPO Lot Size

The Supriya Lifescience IPO market part size is 54 offers. A retail-individual financial backer can apply for up to 13 parcels (702 offers or ₹192,348).

Application         Lots        Shares  Amount (Cut-off)

Minimum            1              54           ₹14,796

Maximum           13           702         ₹192,348

Supriya Lifescience IPO Promoter Holding

Pre Issue Share Holding 99.98%

Post Issue Share Holding               68.24%

Supriya Lifescience IPO Review

SLL has been gaining ground with higher top and main concerns without fail and trading more than 75% of items to in excess of 86 nations. In light of monetary boundaries, the issue is appealingly estimated overlooking something in all cases. The issue merits considering for short to long haul rewards. Peruse detail survey…

Supriya Lifescience IPO Subscription Status (Bidding Detail)

The Supriya Lifescience IPO is bought in 9.72 times on Dec 20, 2021 12:12:00 PM. The public issue bought in 38.92 times in the retail class, 0.87 times in the QIB classification, and 7.95 times in the NII class. Actually take a look at step by step Subscription Details (Live Status)

Classification

Membership (times)

QIB         0.87

NII          7.95

Retail     38.92

Total      9.72